Chengdu Yiyun Technology Co., Ltd. agreed to acquire a 47.35% stake in Guangdong Kangaiduo Digital Health Technology Co., Ltd. from Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE:002433) for approximately CNY 750 million in April 2021. Chengdu Yiyun pays the consideration of this transaction in installments as follows: After satisfying all delivery conditions or Chengdu Yiyun's written exemption, Chengdu Yiyun will pay Guangdong Taiantang Pharmaceutical 60% of the benchmark transfer price, which is CNY 448.878 million; Within 5 working days after the completion of the delivery audit, based on the benchmark transfer price, adjustment amount and the first-phase consideration paid, Chengdu Yiyun will pay Taiantang the difference between the first-phase consideration and the final transfer price (if any) or Taiantang refunded the difference between the initial consideration and the final transfer price (if any) to Chengdu Yiyun; Regarding the advance payment, if Guangdong Kangaiduo Digital Health Technology Co., Ltd. has recovered the relevant amount within the 16th to 30th day from the delivery date and the relevant amount has been adjusted ("post-period withdrawal of advance payment"), the delivery will be confirmed at Taiantang and Chengdu Medical Cloud Within 5 working days after the audit result and the expiration of the 30-day period from the delivery date (whichever occurs later), Chengdu Yiyun will withdraw the advance payment (if any) after the payment period to Taiantang. At the same time, Guangdong Taiantang entrusted the voting rights of the 4% shares of Guangdong Kangaiduo Digital Health Technology to Chengdu Yiyun for exercise. As of May 25, 2021, Chengdu Yiyun Technology Co., Ltd. has paid 60% of the transfer price. As at December 31, 2020, Guangdong Kangaiduo Digital Health Technology had total assets of CNY 1.2 billion and net assets of CNY 272.28 million. For the year ended December 31, 2020, Guangdong Kangaiduo Digital Health Technology had Operating income of CNY 2.8 billion and net profit of CNY 31.57 million. The transaction is subject to general meeting of shareholders of Guangdong Taiantang Pharmaceutical and the transaction plan needs to be approved by more than two-thirds of the shareholders attending the general meeting and the shareholders of Chengdu Yiyun Technology. The transaction report (draft) has been reviewed and approved at the 20th meeting of the fifth Board of Directors of Guangdong Taiantang Pharmaceutical. The transaction plan has been reviewed and approved by the Kangaiduo shareholders meeting, and other shareholders have agreed to waive the right of preemption. The transaction has been approved by the Board of Directors of Chengdu Yiyun Technology. Yang Canxi, Zhang Qincha, Zhong Xiangcheng and Wang Baoshi of Yuekai Securities Co., Ltd. acted as financial advisor, Guo Jia, Chen Wei and Cheng Bing of Grandall (Guangzhou) Law Firm acted as legal advisor and Ge Sanping, Deng Gaofeng and Li Zunnong of Zhongxinghua Certified Public Accountants (Special General Partnership) acted as accountant to Guangdong Taiantang Pharmaceutical.